Bayer Pharmaceuticals secures full ownership of JV with Zydus Lifesciences

Bayer Pharmaceuticals Private Limited will secure full ownership of Bayer Zydus Pharma Private Limited (BZPPL) after concluding its joint venture with Zydus Lifesciences Limited (formerly Cadila Healthcare). This strategic move aligns with the pre-agreed terms of their 50:50 joint venture, which was initially formed on January 28, 2011, to market and sell pharmaceutical products in India.

The joint venture combined the complementary strengths of the two companies, leveraging Zydus Lifesciences’ extensive marketing, sales expertise, distribution network, and industry connections in India. Bayer contributed its global expertise in innovative pharmaceutical solutions and commercialization, driving significant progress across various medical fields, including cardiovascular diseases, diabetes, women’s health, ophthalmology, and oncology.

Bayer Pharmaceuticals secures full ownership of Bayer Zydus Pharma Private Limited joint venture with Zydus Lifesciences, aiming to expand healthcare innovation and market presence in India.

Commenting on the conclusion, Shweta Rai, Managing Director for India and Country Division Head for South Asia, Bayer Pharmaceuticals, emphasized the value of Zydus as a formidable partner in the collaboration. “As we assume full ownership of BZPPL, Bayer remains committed to ensuring its steadfast presence in India. Building on the gains made over more than a decade, we aim to carry forward our mission of ‘Health for All, Hunger for None’.”

This acquisition reflects Bayer’s strategic intent to strengthen its market presence in India by continuing to offer innovative health solutions and addressing the unmet healthcare needs of patients in the region.